Form 4: Avidity Biosciences CHRO Acquires Shares, Sells for Tax

Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, acquired 39,000 shares from PSU vesting and simultaneously sold 17,298 shares to cover tax obligations.

Summary

• Teresa McCarthy, Chief Human Resources Officer of Avidity Biosciences, Inc., acquired 39,000 shares of common stock on December 17, 2025.
• These shares were obtained through the vesting of performance-based restricted stock units (PSUs) originally granted on October 30, 2024.
• The PSUs were accelerated and settled for tax planning purposes.
• Concurrently, 17,298 shares were disposed of at a price of $71.87 per share to cover tax withholding obligations related to the PSU settlement.
• Following these transactions, McCarthy's direct beneficial ownership of common stock is 118,832 shares.

Sentiment

Score: 7

Explanation: The vesting of performance-based units is a positive indicator of performance achievement. The subsequent sale for tax purposes is a neutral, routine event. The overall sentiment is moderately positive due to the underlying performance achievement.

Positives

• The vesting of performance-based restricted stock units indicates the achievement of performance criteria, which is generally positive for the company.
• The acquisition of 39,000 shares increases the insider's direct ownership, aligning management interests with shareholders.

Negatives

• The sale of 17,298 shares, although for tax purposes, reduces the insider's direct ownership.

Risks

• The acquired shares remain subject to recoupment by Avidity Biosciences if the Reporting Person's employment is terminated by the Issuer for cause or by the Reporting Person without good reason.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the details of the stock transactions.

Industry Context

This Form 4 filing details routine insider stock transactions related to executive compensation, specifically the vesting of performance-based restricted stock units and subsequent tax-related sales. It does not provide information directly related to broader industry trends or competitive landscape.

Comparison to Industry Standards

• This filing is a standard Form 4 for executive compensation. The vesting of PSUs and subsequent sale for tax withholding is a common practice across publicly traded companies, particularly in the biotechnology sector, and aligns with typical executive compensation structures. No specific comparable companies or projects are mentioned in the filing.

Stakeholder Impact

• Shareholders: The vesting of performance-based units suggests management has met certain performance targets, which could be viewed positively. The increase in direct ownership (before tax sales) aligns management interests with shareholders.
• Employees: The filing pertains to executive compensation and does not directly impact the broader employee base.

Next Steps

• The filing does not explicitly mention future actions, events, or milestones.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of performance-based restricted stock units and subsequent tax-related sales. While the vesting indicates performance achievement, the transactions themselves are standard and do not provide new material information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as the filing does not present a strong catalyst for either buying or selling.

Keywords

Avidity Biosciences, RNA, Teresa McCarthy, Form 4, Insider Trading, PSU Vesting, Restricted Stock Units, Stock Sale, Tax Withholding, Executive Compensation